KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Accounts Payables (2019 - 2025)

Historic Accounts Payables for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to $19.4 million.

  • Royalty Pharma's Accounts Payables rose 4513.09% to $19.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $19.4 million, marking a year-over-year increase of 4513.09%. This contributed to the annual value of $19.4 million for FY2025, which is 4513.09% up from last year.
  • According to the latest figures from Q4 2025, Royalty Pharma's Accounts Payables is $19.4 million, which was up 4513.09% from $41.4 million recorded in Q3 2025.
  • Royalty Pharma's Accounts Payables' 5-year high stood at $41.4 million during Q3 2025, with a 5-year trough of $5.6 million in Q4 2021.
  • For the 5-year period, Royalty Pharma's Accounts Payables averaged around $15.3 million, with its median value being $12.8 million (2022).
  • As far as peak fluctuations go, Royalty Pharma's Accounts Payables plummeted by 7266.78% in 2021, and later soared by 30309.86% in 2024.
  • Quarter analysis of 5 years shows Royalty Pharma's Accounts Payables stood at $5.6 million in 2021, then surged by 40.68% to $7.9 million in 2022, then skyrocketed by 91.82% to $15.2 million in 2023, then dropped by 11.84% to $13.4 million in 2024, then soared by 45.13% to $19.4 million in 2025.
  • Its Accounts Payables was $19.4 million in Q4 2025, compared to $41.4 million in Q3 2025 and $20.2 million in Q2 2025.